neuraxis.com (NRXS): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
NeurAxis, Inc. (NRXS) collaborates closely with specialized clinics to implement methods for combating abdominal pain in youth. Due to its status as a leading developer in pediatrics, the brand enjoys the absolute trust of physicians. The price action on GURU.Markets confirms its status as a neurostimulation leader, where product uniqueness ensures a stable cash flow and a margin of 0.00, generating benchmark profits.
Analytical breakdowns for NeurAxis, Inc.
- stock price and consensus target price:
- stock exchange capitalization data:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Capital NeurAxis, Inc.|NRXS - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity NeurAxis|NRXS - Company Total Debt Obligations|Debt to Book Value NeurAxis Inc|NRXS - Company Long-Term Loans and Borrowings|Company Short-Term Debts NeurAxis|Quick Liquidity neuraxis.com
- financial results and valuation multiples details:
NRXS - Company Profit|Projected Future Earnings NeurAxis, Inc.|NRXS - Price to Earnings Ratio|Projected Price to Earnings NeurAxis, Inc.|NRXS - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeurAxis Inc|NRXS - Operating profit before amortization|Earnings per share for the last twelve months NeurAxis|NRXS - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months neuraxis.com|NRXS - Earnings per share growth this year|Net earnings per share growth forecast for next year NeurAxis, Inc.
Comprehensive company analysis:NeurAxis, Inc (NRXS)
Investors are assessing the resilience of NeurAxis, Inc. (NRXS) through the ratio of enterprise value, including net debt, to EBITDA. By analyzing the EV/EBITDA multiple chart for the business, one can understand how ESG compliance costs and the implementation of digital diagnostics impact the company's fundamental value relative to its ability to generate cash flow under high debt leverage.
Key competitors
Biogen Corp - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Neurocrine Corp NBIX|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation AXSM (axsome.com)|ACAD: EV/EBITDA Multiple|Xenon Pharmaceuticals Inc. (XENE) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio VKTX|Enterprise Value to Operating Income Before Depreciation SUPN (Supernus Corp)|EV/EBITDA Multiple CPRX|Total Company Value to Operating Income Before Depreciation Ratio denalitherapeutics.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harmony Biosciences Holdings, Inc. HRMY|Total Company Value to Operating Income Before Depreciation Ratio Biohaven Ltd (BHVN)|AMLX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation TRVI (Trevi Corp)|PRAX: EV/EBITDA Multiple|AVXL - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CeriBell|Enterprise Value to Operating Income Before Depreciation PRTA (Prothena Corporation PLC)|EV/EBITDA Multiple ALEC|Enterprise Value to EBITDA Ratio Annexon Biosciences Inc. ANNX|Omeros - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio neurogene.com (NGNE)|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VYGR (Voyager Therapeutics Inc) - Enterprise Value to Operating Income Before Depreciation|Neumora Therapeutics Inc (NMRA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Scilex Holding Company, Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio TVGN|Enterprise Value to Operating Income Before Depreciation ACOG (Alpha Cognition Corp)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cognition Therapeutics, Inc. (CGTX)|Total Company Value to Operating Income Before Depreciation Ratio Inhibikase Therapeutics Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cassava SAVA|ASRT: Enterprise Value to Operating Income Before Depreciation|Coya - EV/EBITDA Multiple|Company Value to EBITDA Vistagen Therapeutics|OVID (ovidrx.com) - Enterprise Value to EBITDA Ratio|Acumen Pharmaceuticals Inc. (ABOS) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CervoMed Inc|ATHE: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Clene Inc. (CLNN)|PEPG - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jupiter Neurosciences JUNS|RLMD: Enterprise Value to Operating Income Before Depreciation|Annovis Bio Corp - EV/EBITDA Multiple|Company Value to EBITDA Grace Therapeutics, Inc.|AIFF (Firefly Neuroscience, Inc) - Enterprise Value to EBITDA Ratio|Klotho Neurosciences (KLTO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics Ltd|RVPH: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple MTVA|EV/EBITDA Multiple heliusmedical.com (HSDT)|Passage Bio - Enterprise Value to EBITDA Ratio|NEUP: Enterprise Value to Operating Income Before Depreciation|Minerva Neurosciences, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Athira Pharma Inc ATHA|Addex Therapeutics, Ltd. (ADXN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ALZN - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio CYCN|PTIX: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple KTTA|Total Company Value to Operating Income Before Depreciation Ratio cortigent.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avenue Therapeutics, Inc ATXI|BCLI: Enterprise Value to Operating Income Before Depreciation|Cara Therapeutics, Inc. - EV/EBITDA Multiple|chromocell.com (CHRO) - Enterprise Value to EBITDA Ratio|ELYM (eliemtx.com) - Enterprise Value to EBITDA Ratio|ITCI - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharma|Enterprise Value to Operating Income Before Depreciation MRNS (Marinus Pharma)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NKGen Biotech, Inc. (NKGN)|NRBO (neurobopharma.com) - Business Value to Operating Income Before Depreciation|Sage Therapeutics - Enterprise Value to EBITDA Ratio|SNPX: Enterprise Value to Operating Income Before Depreciation|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Vigil Neuroscience VIGL|Anew Medical, Inc. (WENA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation CERE
